S
EPZM

SignatureFD’s Epizyme, Inc EPZM Stock Holding History

SignatureFD’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-565
Closed -$1K – 3396
2021
Q4 		$1K Buy
+565
New +$2.22K ﹤0.01% 3067
2021
Q3 		– Sell
-234
Closed -$2K – 3283
2021
Q2 		$2K Buy
234
+233
+23,300% +$1.96K ﹤0.01% 2654
2021
Q1 		$0 Sell
1
-82
-99% -$848 ﹤0.01% 2869
2020
Q4 		$1K Hold
83
– – ﹤0.01% 2518
2020
Q3 		$1K Sell
83
-75
-47% -$1K ﹤0.01% 2545
2020
Q2 		$3K Buy
158
+52
+49% +$908 ﹤0.01% 2055
2020
Q1 		$2K Buy
106
+102
+2,550% +$2.19K ﹤0.01% 2035
2019
Q4 		$0 Hold
4
– – ﹤0.01% 2324
2019
Q3 		$0 Hold
4
– – ﹤0.01% 2248
2019
Q2 		$0 Hold
4
– – ﹤0.01% 2205
2019
Q1 		$0 Buy
+4
New +$45 ﹤0.01% 2089

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SignatureFD's EPZM Position: Q1 2022 in Review

SignatureFD sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 565 shares — an estimated $1K sold.

SignatureFD first reported a position in EPZM in Q1 2019 and held it in 11 quarters. The position peaked at $3K in Q2 2020. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

  • SignatureFD reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
  • SignatureFD sold 565 Epizyme, Inc shares in Q1 2022, an estimated $1K.
  • SignatureFD first reported a position in Epizyme, Inc in Q1 2019 and held it in 11 quarters.
  • SignatureFD's Epizyme, Inc position peaked at $3K in Q2 2020.
  • 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on SignatureFD's 13F filing for Q1 2022, filed 2 May 2022.